Prelude Therapeutics Aktie (PRLD)

Prelude Therapeutics Incorporated is a precision oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. By focusing on developing molecules using broad mechanisms that have multiple links to oncogenic driver pathways in select patients, it has developed a diverse pipeline consisting of multiple distinct programs, including kinases, targeted protein degraders, and degrader antibody conjugates. PRT12396 its lead, mutant-selective JAK2V617F inhibitor, is an open-label and multi-center study in patients with high-risk polycythemia vera and intermediate and high-risk myelofibrosis. JAK2V617F is the primary driver mutation responsible for disease progression in the majority of patients living with myeloproliferative neoplasms. The Company has discovered and is developing a series of selective and orally bioavailable KAT6A selective degraders. KAT6A is engaged in treating advanced breast cancer & other solid tumors.